乾癬性関節炎におけるイキセキズマブの安全性: Data ４臨床試験からの2000人年超の曝露データ
doi: 10.1136/annrheumdis-2021-222027
This analysis aimed to report the safety profile of ixekizumab for the PsA SPIRIT programme. The overall safety profile and tolerability of ixekizumab are consistent with the previously known safety profile in patients with PsA.